Biopotency and site of action of drugs affecting testicular steroidogenesis

in Journal of Endocrinology
Authors:
A. Lambert
Search for other papers by A. Lambert in
Current site
Google Scholar
PubMed
Close
,
R. Mitchell
Search for other papers by R. Mitchell in
Current site
Google Scholar
PubMed
Close
, and
W. R. Robertson
Search for other papers by W. R. Robertson in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

ABSTRACT

The effect of etomidate (an anaesthetic), epostane (WIN 32729; an inhibitor of ovarian and adrenal steroidogenesis) and cyproterone acetate (an antiandrogen) on testosterone secretion from mouse Leydig cells stimulated with LH (5 i.u./l) was tested. The concentration of drug which inhibited testosterone secretion by 50% was 11·5±1·1 (s.e.m.) μmol/l for cyproterone acetate, 1·2 ± 0·2 μmol/l for etomidate and 0·23 ± 0·03 μmol/l for epostane.

The effect of all three drugs on testicular steroidogenesis was completely reversible. Thus testicular cells which had been washed after exposure to a >95% inhibitory dose of drug responded in a similar manner to hormone stimulation as cells similarly washed and which had not been exposed to the drug.

The sites of the antisteroidogenic effect of epostane, etomidate and cyproterone acetate were established using a method based on the sequential stimulation by the exogenous precursor steroids of the various steps leading to the biosynthesis of testosterone. It was concluded that etomidate acts at the sequence between LH binding and pregnenolone production, epostane acts at 3β-hydroxysteroid dehydrogenase and cyproterone acetate inhibits 3β-hydroxysteroid dehydrogenase and C17,20-lyase.

J. Endocr. (1987) 113, 457–461

 

  • Collapse
  • Expand